Further, we have identified a small subset of luminal A breast cancers (7–24%) that are CREB3L1-deficient, suggesting that this subgroup of luminal A breast cancers is likely to be more metastatic and could be identified and treated with chemotherapy agents to improve the outcomes of these patients. This evidence concerns the gene CREB3L1 and breast carcinoma.